FAK inhibitor suppresses ovarian cancer growth by inhibiting tumor angiogenesis
Abstract Background Ovarian cancer, the second deadliest gynecological malignancy, necessitates the identification of novel therapeutic targets. Focal adhesion kinase (FAK), a non-receptor tyrosine kinase, has emerged as a promising target for ovarian cancer treatment owing to its diverse regulatory...
Guardat en:
| Autors principals: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2026-05-01
|
| Col·lecció: | Cancer Cell International |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s12935-026-04325-z |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|